Share on StockTwits

Smith & Nephew plc (LON:SN) has been given a consensus rating of “Hold” by the nineteen analysts that are currently covering the stock, AR Network reports. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is GBX 973.50 ($16.53).

SN has been the subject of a number of recent research reports. Analysts at Investec downgraded shares of Smith & Nephew plc to an “add” rating in a research note on Friday. They now have a GBX 1,100 ($18.68) price target on the stock. Separately, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Smith & Nephew plc in a research note on Friday. They now have a GBX 980 ($16.64) price target on the stock. Finally, analysts at Panmure Gordon reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Friday. They now have a GBX 975 ($16.56) price target on the stock.

Shares of Smith & Nephew plc (LON:SN) opened at 1065.00 on Wednesday. Smith & Nephew plc has a 52-week low of GBX 737.50 and a 52-week high of GBX 1136.00. The stock’s 50-day moving average is GBX 1043.43 and its 200-day moving average is GBX 957.2. The company’s market cap is £9.510 billion.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.